ReviewBMC pediatrics2018
Pediatric severe asthma: a case series report and perspectives on anti-IgE treatment.
Review in BMC pediatrics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Safety of biologics for the treatment of asthma in children and adolescents: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Demographic and Clinical Insights into Pediatric Asthma Exacerbations: A Retrospective Study at a Tertiary Care Center in the United Arab Emirates.Avicenna journal of medicine · 2026Article
- Unanswered questions on the use of biologics in pediatric asthma.The World Allergy Organization journal · 2023Review
- Ιnterleukin-17A-Enriched Neutrophil Extracellular Traps Promote Immunofibrotic Aspects of Childhood Asthma Exacerbation.Biomedicines · 2023Article
- Severe asthma in children: An official statement from Saudi Pediatric Pulmonology Association.Saudi medical journal · 2022Article
- Current Status of Pediatric Formulations for Chronic and Acute Children' Diseases: Applications and Future Perspectives.Medeniyet medical journal · 2021Review
- The impact of asthma-exclusive nursing scheme on the treatment effect of asthma patients.American journal of translational research · 2021Article
- Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children.Asia Pacific allergy · 2019Review
- Advances in pediatrics in 2017: current practices and challenges in allergy, endocrinology, gastroenterology, genetics, immunology, infectious diseases, neonatology, nephrology, neurology, pulmonology from the perspective of Italian Journal of Pediatrics.Italian journal of pediatrics · 2018Review
- Asthma: Differential Diagnosis and Comorbidities.Frontiers in pediatrics · 2018Review
- New Drugs for Pediatric Asthma.Frontiers in pediatrics · 2018Review
- Home Monitoring of Asthma Exacerbations in Children and Adults With Use of an AI-Aided Stethoscope.Annals of family medicineObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe primary goal of asthma management is to achieve disease control for reducing the risk of future exacerbations and progressive loss of lung function. Asthma not responding to treatment may result in significant morbidity. In many children with uncontrolled symptoms, the diagnosis of asthma may be wrong or adherence to treatment may be poor. It is then crucial to distinguish these cases from the truly "severe therapy-resistant" asthmatics by a proper filtering process. Herein we report on four cases diagnosed as difficult asthma, detail the workup that resulted in the ultimate diagnosis, and provide the process that led to the prescription of omalizumab. CASE PRESENTATION: All children had been initially referred because of asthma not responding to long-term treatment with high-dose inhaled steroids, long-acting β
conclusionsThe management of asthma is becoming much more patient-specific, as more and more is learned about the biology behind the development and progression of asthma. The addition of omalizumab, the first targeted biological treatment approved for asthma, has led to renewed optimism in the management of children and adolescents with atopic severe asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.